Thrombin generation capacity of methylene blue-treated plasma prepared by the theraflex MB plasma system

Transfusion Medicine and Hemotherapy

Volumn 36, Issue 2, 2009, Pages 122-127

  Gravemann, Ute ^a,c   Kusch, Manuela ^b   Koenig, Herbert ^b   Mohr, Harald ^a   Mueller, Thomas H ^a  

^a DRK Blutspendedienst NSTOB   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c DRK Blutspendedienst NSOB   (Germany)

Author keywords

MB plasma; Theraflex MB plasma system; Thrombin generation capacity

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; METHYLENE BLUE; THROMBIN;

ARTICLE; BLOOD CLOTTING; BLOOD DONOR; CONTROLLED STUDY; FILTRATION; HUMAN; LEUKOPENIA; PLASMA; THROMBIN TIME;

EID: 65349148583     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000202413     Document Type: Article

References (32)

1. Mohr H, Lambrecht B, Selz A: Photodynamic virus inactivation of blood components. Immunol Invest 1995;24:73-85.
2. Mohr H, Knuver-Hopf J, Gravemann U, Redecker- Klein A, Muller TH: West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004;44:886-890.
3. Williamson LM, Cardigan R, Prowse CV: Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43: 1322-1329.
4. Girones N, Bueno JL, Carrion J, Fresno M, Castro E: The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006;91:285-291.
5. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV: A potentially improved approach to methylene blue virus inactivation of plasma: The maco pharma maco-tronic system. Transfus Med 2001;11:31-36.
6. Garwood M, Cardigan RA, Drummond O, Hornsey V, Turner CP, Young D, Williamson LM, Prowse CV: The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003;43: 1238-1247.
7. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ: Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein s in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004;14:39-44.
8. Cardigan R, Allford S, Williamson L: Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 2002;117:253-254.
9. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Muller C, Heuft HG, Huhn D: The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994;34:685-689.
10. Henschen-Edman AH: Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversion. Cell Mol Life Sci 1997;53:29-33.
11. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S: The calibrated automated thrombogram (cat): A universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002;32: 249-253.
12. Tapp HJ, Grundmann C, Kusch M, Koenig H: Thrombin generation assay based on a certain substrate allows a simplified calibration procedure. Hämostaseologie 2008;28:A65.
13. Lawrie AS, Cardigan RA, Williamson LM, Machin SJ, Mackie IJ: The dynamics of clot formation in fresh-frozen plasma. Vox Sang 2008;94:306-314.
14. Pock K, Heger A, Janisch S, Svae TE, Romisch J: Thrombin generation capacity is impaired in methylene- blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas®) and a development product (Uniplas®). Transfus Apher Sci 2007;37:223-231.
15. Heger A, Romisch J, Svae TE: A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006;35:223-233.
16. Paul-Ehrlich-Institut, Bundesärztekammer: Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwenduung von Blutprodukten (Haemotherapie). Köln, Deutscher Ärzte-Verlag, 2001.
17. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M: Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006;16:266-275.
18. Funk C, Gmur J, Herold R, Straub PW: Reptilase-r - a new reagent in blood coagulation. Br J Haematol 1971;21:43-52.
19. Suzuki K, Nishioka J: Plasma protein s activity measured using Protac, a snake venom derived activator of protein C. Thromb Res 1988;49:241-251.
20. Preda L, Tripodi A, Valsecchi C, Lombardi A, Finotto E, Mannucci PM: A prothrombin timebased functional assay of protein S. Thromb Res 1990;60:19-32.
21. Dusel CH, Grundmann C, Eich S, Seitz R, Konig H: Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 2004;15:405-411.
22. Kawabata S, Miura T, Morita T, Kato H, Fujikawa K, Iwanaga S, Takada K, Kimura T, Sakakibara S: Highly sensitive peptide-4-methylcoumaryl-7- amide substrates for blood-clotting proteases and trypsin. Eur J Biochem 1988;172:17-25.
23. Hellstern P, Sachse H, Schwinn H, Oberfrank K: Manufacture and in vitro characterization of a solvent/ detergent-treated human plasma. Vox Sang 1992;63:178-185.
24. Politis C, Kavallierou L, Hantziara S, Katsea P, Triantaphylou V, Richardson C, Tsoutsos D, Anagnostopoulos N, Gorgolidis G, Ziroyannis P: Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the theraflex methylene blue system including the blueflex filter: 5 years' experience. Vox Sang 2007;92:319-326.
25. Osselaer JC, Debry C, Goffaux M, Pineau J, Calomme G, Dubuc E, Chatelain B, Vandendaele MC, Hsu J, Rheinschmidt M, Lin L: Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008;48:108-117.
26. Depasse F, Sensebe L, Seghatchian J, Andreu G, Samama MM: The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices. Transfus Apher Sci 2005;33:63-69.
27. Inada Y, Hessel B, Blomback B: Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta 1978;532:161-170.
28. Suontaka AM, Blomback M, Chapman J: Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 2003;43:568-575.
29. Wolberg AS: Thrombin generation and fibrin clot structure. Blood Rev 2007;21:131-142.
30. Butenas S, Mann KG: Caution in the interpretation of continuous thrombin generation assays. J Thromb Haemost 2007;5:1084-1085; author reply 1085-1087.
31. Dargaud Y, Luddington R, Gray E, Negrier C, Lecompte T, Petros S, Hogwood J, Bordet JC, Regnault V, Siegemund A, Baglin T: Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007;139:303-309.
32. Hemker HC, Al Dieri R, De Smedt E, Beguin S: Thrombin generation, a function test of the haemostatic- thrombotic system. Thromb Haemost 2006; 96:553-561.